VNDA
Vanda Pharmaceuticals Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 23 to Mar 2 ▼ 2 days of insider sells: $1.9M by 3 insiders, avg $8.17
- Mar 30 1:23-cv-00152 Vanda Pharmaceuticals Inc. v. Teva…
- May 6 Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY),…
- Sep 2 Trial readout: T-90d Trial Readout: VQW-765 (Phase 3)
- Sep 23 Oppenheimer initiates
- Oct 12 Trial readout: Results Pending: Tasimelteon (Phase 3), Completed 38d ago
- Oct 28 ▲ Vanda Pharmaceuticals reported Q3 2026 total revenue of $69.8M, up 2…
- Oct 28 ▲ Earnings: VNDA Q3 2026 Earnings: EPS $-0.37 (+46.8% vs est)
- Nov 3 to Nov 5 ▲ 3 days of insider buys: $38.1K by 1 insider, avg $3.81
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $38.1K at an average $3.81. 3 insiders sold $1.9M.
- InstitutionsMIXED
Q3 2026: 17 added (0 new), 20 trimmed or exited.
- AnalystsBULLISH
9 of 11 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate −$0.362 → −$0.302 over 90 days.
- Short sellersSTEADY
Short interest −8.3% to 7.62M shares. 5.9 days to cover, ≈12.6% of shares.
- TrendDOWNTREND
15% below its 50-day average.
- SocialQUIET
Crowd 58° (warm) this week from 2 mentions: 1 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | ADD | $10.2M |
| FEDERATED HERMES, INC. | DOUBLED | $7.9M |
| Qube Research & Technologies Ltd | ADD | $6.1M |
| FMR LLC | DOUBLED | $1.5M |
| BARCLAYS PLC | DOUBLED | $931.3K |
| KLP KAPITALFORVALTNING AS | ADD | $907.4K |
| IEQ CAPITAL, LLC | TRIM | $639.7K |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | $620.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analysts| Date | Firm | Rating |
|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 23, 2026 | Oppenheimer INITIATE | Outperform |
| Aug 10, 2026 | B. Riley Securities REITERATE | Buy |
| Aug 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Duncan Charles Cliff Director Nov 5, 2026 | BUY | $22.1K |
Duncan Charles Cliff Director Nov 4, 2026 | BUY | $13.2K |
Duncan Charles Cliff Director Nov 3, 2026 | BUY | $2.8K |
Mitchell Stephen Ray Director Jun 4, 2026 | AWARD | 41,600 sh |
Honore Tage Director Jun 4, 2026 | AWARD | 41,600 sh |
Ward Anne Sempowski Director Jun 4, 2026 | AWARD | 41,600 sh |
Duncan Charles Cliff Director Jun 4, 2026 | AWARD | 41,600 sh |
Chrousos Phaedra Director Jun 4, 2026 | AWARD | 41,600 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.30 | -$0.39–-$0.23 | +38.9% | $70.1M |
| Next Q | -$0.25 | -$0.32–-$0.16 | +39.8% | $72.4M |
| Current FY | -$2.52 | -$2.61–-$2.45 | +16.7% | $242.1M |
| Next FY | -$0.74 | -$1.47–$0.07 | +23.0% | $316.3M |
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 1 bullish · 0 bearish · 1 mixed · 6 neutral- NEUTRAL SC 13G/ANov 13, 2026
AQR Capital Management filed an amended Schedule 13G disclosing a 3.47% passive stake in Vanda…
AQR's reduction to below 5% removes the need for future 13G filings, but the passive nature and small stake size limit any signal. Monitor for any further institutional trimming or conversion to 13D…
- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing a 5.0% passive stake in Vanda…
Three institutional holders now hold 5%+ passive stakes, indicating strong institutional conviction. Monitor for any 13D conversion or additional stake accumulation by these holders, though all…
- BULLISH 8-KOct 28, 2026
Vanda Pharmaceuticals reported Q3 2026 total revenue of $69.8M, up 24% YoY and above the $69.1M…
The revenue beat and EPS surprise, combined with declining operating expenses and positive pipeline catalysts (NEREUS GLP-1 Phase III, BYSANTI launch, Quimilza PDUFA), support a positive outlook…
- NEUTRAL SC 13GOct 27, 2026
BlackRock Portfolio Management LLC filed a Schedule 13G disclosing a 5.9% passive stake in Vanda…
Monitor for any future amendments that could signal a shift from passive to active intent, or further accumulation by BlackRock or other large holders. The combined 12.9% held by BlackRock and…
All VNDA filing & press-release reports (8)
- SC 13G/A reportNov 13, 2026
- SC 13G reportNov 10, 2026
- 8-K reportOct 28, 2026
- SC 13G reportOct 27, 2026
- PRESS-RELEASE reportOct 21, 2026
- SC 13G/A reportOct 9, 2026
- PRESS-RELEASE reportJul 29, 2026
- 8-K reportMay 6, 2026